CASTLEFORD, England, March 26, 2012 /PRNewswire/ --
We are pleased to announce the launch of generic Quetiapine film-coated tablets and Quetiapine (Sondate) XL tablets, on day one of patent expiry.
Quetiapine is a generic version of Seroquel®▼ (Quetiapine) by AstraZeneca UK Limited. It is indicated in the treatment of schizophrenia and the treatment of moderate to severe manic episodes. Quetiapine (Sondate) XL is a generic version of Seroquel® XL▼ by AstraZeneca UK Limited. It is indicated in the treatment of schizophrenia and bipolar disorder, and add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy*. Please read Summary of Product Characteristics for more in-depth information.
Both versions are available immediately on Teva's PriceWatch service, which is guaranteed to match the month's average market price or Teva's list price - whichever is lower.
Quetiapine film-coated tablets
Strength 25mg 100mg 150mg 200mg 300mg
Brand Price GBP40.50 GBP113.10 GBP113.10 GBP113.10 GBP170.00
Initial Teva Retail
Price GBP6.08 GBP16.97 GBP16.97 GBP16.97 GBP25.50
Quetiapine (Sondate) XL tablets
Strength 50mg 200mg 300mg 400mg
Brand Price GBP67.66 GBP113.10 GBP170.00 GBP226.20
Initial TEVA Retail
Price GBP50.75 GBP84.83 GBP127.50 GBP169.65
Kim Innes, Commercial Director said: "With the launch of Quetiapine and Quetiapine XL, we're making more medicines accessible for more people. We've now launched ten new products in eleven weeks, including seven on day-one of patent-expiry. It adds to what is the UK's widest portfolio of medicines, with over 700 products. But, importantly launches like these help towards saving the NHS over £9bn on generic prescriptions."
Teva products are available through major wholesalers, local Territory Managers or contact +44(0)800-085-8621 .
Visit Teva online at http://www.tevauk.com
*Quetiapine (Sondate) XL is indicated for: preventing relapse in stable schizophrenic patients who have been maintained on Quetiapine. In the treatment of bipolar disorder, for the: treatment of moderate to severe manic episodes in bipolar disorder; treatment of major depressive episodes in bipolar disorder; and the prevention of recurrence in patients with bipolar disorder, in patients whose manic or depressive episode has responded to quetiapine treatment; add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD), who have had sub-optimal response to antidepressant monotherapy. Prior to initiating treatment, clinicians should consider the safety profile of quetiapine.
Notes to Editors:
About Teva UK Limited
Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.
About Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.
For media enquiries, contact the Teva UK Limited Media team on +44(0)1977-628500, or email media.enquiries@tevauk.com.
Share this article